ROKIT Healthcare is expanding its entry into the public health care markets of the Middle East and South America. Starting with supplies to a national hospital in Kuwait, it is broadening its overseas foothold by securing a patent in Bahrain and participating in public hospital tenders in Argentina.
ROKIT Healthcare said on the 22nd that it recently received a purchase order from the Kuwaiti government to supply its 3D bioprinting-based skin regeneration platform to national hospitals. The company said the supply will proceed through a local partner and is expected to serve as a springboard into the Middle Eastern public health care market.
The company also received a decision this month from the Bahrain patent office to register a patent for "bio-ink compositions for cartilage regeneration and a method of manufacturing customized scaffolds for cartilage regeneration." The technology is a customized cartilage regeneration approach that combines artificial intelligence (AI) with 3D bioprinting.
Its expansion into the South American market is also accelerating. The company said it received approval from the Buenos Aires provincial health authorities in Argentina to use the Dr. INVIVO 3D bioprinter in public hospitals and has also started a public tender to supply treatment kits.
In Argentina, there was also a case covered by PAMI, the national health insurance program. The company said it plans to expand the scope of treatment within the public health care system.
In neighboring Uruguay, a clinical study on patients with diabetic foot confirmed the effectiveness of treating chronic ulcers, and additional clinical trials are underway.
ROKIT Healthcare plans to expand the scope of application from skin regeneration treatments to long-term regeneration areas such as skin recovery after cancer reconstructive surgery.